MIS-C Cases are Rare and Unrelated to COVID-19 Vaccination

A peer-reviewed study published in The Lancet Child & Adolescent Health on Feb. 22, 2022, suggests that identifying Multisystem inflammatory syndrome (MIS-C) in teenagers after COVID-19 vaccination is a rare occurrence.

This finding was based on nine months of follow-up data on people between 12 to 20 who had received at least one dose of the Pfizer-BioNTech COVID (Comirnaty) mRNA vaccine from Dec. 14, 2020, to Aug. 31, 2021.

According to the U.S. CDC, the average age of an MIS-C patient is nine years, 60% are male, and 59% are Latino or Black.

Since mid-May 2020, the CDC has confirmed 6,851 cases and 59 fatalities related to MIS-C during the COVID-19 pandemic.

Furthermore, MIS-C was not observed in the 46,000 individuals aged 16 years or older who participated in safety clinical trials for the mRNA vaccine.

U.S. providers are encouraged to report potential MIS-C cases after COVID-19 vaccination to VAERS.

Note: these researchers disclosed various industry relationships.